Agilent Technologies and Integrated Diagnostics have formed a strategic partnership to develop protein-based assays that detect major human diseases at an early stage.

Under the partnership, the companies will develop high-throughput automated workflows that will include sample preparation and LC MS / MS analysis.

Integrated Diagnostics has purchased two Agilent 1290 Infinity UHPLC systems, two 6490 iFunnel triple quadrupole mass spectrometry systems and two 1260 LCs with ultraviolet detectors for the project. Integrated Diagnostics president and chief scientific officer Paul Kearney said Agilent provides an innovative platform upon which next-generation multiplexed proteomic assays can be developed and deployed.

"Integrated Diagnostics will bring expertise in assay development, technology strategy, study design, clinical development, commercialisation and systems informatics to leverage the Agilent technology solution,” Kearney said. ”Our partnership with Agilent will allow us to realise the advantages of using a single technology platform from discovery and verification through to commercialisation."

Agilent Biological Systems Division vice-president and general manager Gustavo Salem said Agilent and Integrated Diagnostics share the vision of harnessing the power of an integrative systems biology approach to solving health challenges. According to Agilent, the technology allows the screening of several hundred biomarkers in a single assay, in a high-throughput and quantitative fashion.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.